Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Transplant nephrology
Would you recommend routinely checking ANCA levels just prior to a planned kidney transplantation in patients with a history of ESKD secondary to ANCA-associated vasculitis?
Related Questions
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
How do you approach the management of a kidney transplant recipient who develops de novo donor-specific antibodies but shows no clinical signs of rejection or graft dysfunction?
What are the best practices for preparing blood for transfusion in a patient with a kidney transplant to minimize complications?
Would you proceed with renal transplant in a patient with lupus nephritis who has progressed to ESRD and is clinically stable, but has persistently elevated dsDNA and low complements despite appropriate doses of hydroxychloroquine and mycophenolate?
Do you have specific waiting periods before a patient can be listed for a kidney transplant if they have a past history of malignancy?
How much proteinuria would warrant consideration of native kidney nephrectomies at the time of a kidney transplant?
What is your approach to dose adjusting mycophenolate in a kidney transplant recipient who is transitioned from tacrolimus to cyclosporine?
What is your approach for patients with a history of nephrolithiasis who are being evaluated for living kidney donation?
How long do you wait for a reduction in EBV viral load after reducing immunosuppression before deciding to start rituximab in a kidney transplant patient with EBV viremia?
How do you approach kidney transplant evaluation and management in an ESKD patient with a history of anti-GBM disease and currently detectable anti-GBM antibodies?
